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496Immune Reconstitution following Myeloablative
Allogeneic Hematopoietic Stem Cell Transplantation:
The Impact of Expanding CD28negative CD81
T Cells on Relapse
Ibrahim Yakoub-Agha,1,2,3 Pasquine Saule,2,3 Leonardo Magro,1 Pascale Cracco,2
Alain Duhamel,4 Valerie Coiteux,1 Benedicte Bruno,1 Franc¸oise Dufosse,2
Jean-Pierre Jouet,1,2,3 Jean-Paul Dessaint,2,3 Myriam Labalette2,3Allogeneic stem cell transplantation has become standard therapy for hematologic malignancies through the
positive immunologic graft-versus-leukemia effect. Initial immune recovery relies on peripheral expansion of
infused T cells, which switch to a memory-like phenotype. This study prospectively investigated whether
changes in subset composition precedes complications after myeloablative HLA-matched transplantation
for hematologic malignancies. Of 80 allograft recipients, 18 were still free of clinical complication throughout
395 to 1564 days of follow-up. Compared with this complication-free subgroup, patients who developed
chronic graft-versus-host disease (cGVHD) without relapsing recovered similar numbers of circulating T
cells with predominance of CD81 T cells lacking CC-chemokine receptor-7 and CD28 expression through-
out the first year after transplantation. Conversely, poor CD81 T cell recovery with diminished numbers of
CD28neg CD81 T cells (1/4th of that of relapse-free patients) preceded occurrence of malignant relapse. In
multivariate analysis, lower CD28neg CD81 T cell counts by day 60 postallograft were associated with
a greater risk of subsequent relapse (hazard ratio [HR] 0.33; 95% confidence interval [CI]: 0.14-0.76; P 5
.01). Enumeration of CD28neg CD81 T cells in patients could assist in predicting risk of relapse and help build
an algorithm for accelerating the immune recovery by reducing the immunosuppressive treatment and
considering the introduction of preemptive donor lymphocyte infusions.
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6/j.bbmt.2008.11.038(TRM) in the early period following allogeneic stem
cell transplantation (allo-SCT). However, relapse of
the underlying hematologic malignancy and chronic
graft-versus-host disease (cGVHD) remain major
causes of treatment failure. Other cell lineages not-
withstanding, mature T cells contained in or derived
from the allograft exert powerful antitumor effects
through the graft-versus-leukemia (GVL) reaction
[1], but T cell-mediated responses can also induce
GVHD [2]. Initial T cell recovery is primarily depen-
dent on peripheral expansion of donor mature T cells
(termed homeostatic peripheral expansion), because de
novo generations of naı¨ve T cells from donor hemato-
poietic stem cells is compromised following cytore-
ductive regimens and cannot have a full impact on
immune reconstitution for 1 or several years, depend-
ing on recipient age [3-7]. Homeostatically expanding
T cells show memory-like phenotypes [3-8] and the
high homeostatic proliferation following lymphopenia
can facilitate expansion of antitumor immunity [7].
Therefore, malignant relapse might result from
Biol Blood Marrow Transplant 15:496-504, 2009 497CD81CD28neg T cells and Relapse after allo-SCTinsufficient homeostatic peripheral expansion, and con-
versely, peripheral expansionwith a too strong immune
reaction against host antigens might induce GVHD.
The purpose of this prospective study was to ad-
dress whether differences in the dynamics of CD4
and CD8 T cell recovery within the first year after
allo-SCT can be related to the absence or occurrence
of malignant relapse and GVHD. The expression
pattern of surface markers in peripheral blood was
analyzed longitudinally in 80 patients after myeloabla-
tive HLA-matched allo-SCT for hematologic malig-
nancies, to categorize T cells with a naı¨ve phenotype
and the phenotypically distinct subsets of memory-
type T cells (ie, central memory and effector memory
cells) [9]. Expression of the costimulation receptor,
CD28, was also analyzed, because CD28 expression
is lost after several rounds of cell division, and segre-
gating CD81T cells by CD28 stainingmight be indic-
ative of their functional capacities [10,11]. In a first
step, we concentrated on 3 subgroups of recipients ac-
cording to whether or not they had developed only 1
posttransplant complication: 1 without evidence of
infection, GVHD, or relapse throughout the whole
period of follow-up; 1 with only cGVHD; and 1 with
only evidence of a malignant relapse after transplanta-
tion. These subgroups allowed comparing kinetics of
T cell recovery in the absence of possible interferences
by other clinical complications. Poor recovery of the
CD81 T cell compartment by 2 months postgraft,
resulting in reduced numbers of CD81 T cells that
lacked CD28 expression, was significantly correlated
with later occurrence of malignant relapse, as verified
in a second step by univariate and multivariate analyses
of the entire cohort.MATERIALS AND METHODS
Patients
From October 2003 on, absolute counts and rela-
tive frequencies of peripheral blood T cell subsets
were determined prospectively in 80 allo-SCT recipi-
ents. Their demographic and clinical characteristics
are given in Table 1. All patients (and parents of chil-
dren) provided informed consent, with approval from
our institutional ethics committee. All patients were
treated for a hematologic malignancy; all were in com-
plete hematologic remission at time of transplantation,
and none were at high risk of relapse after allo-SCT. A
slight majority of patients received myeloablative
conditioning including radiation and chemotherapy
instead of myeloablative chemotherapy alone. All
patients underwent T cell-replete allo-SCT followed
by standard GVHD prophylaxis with cyclosporine
(CsA) and short-termmethotrexate (MTX). For all pa-
tients, it was their first transplantation. Stem cell
source was bone marrow in the majority of patients(n5 67) and otherwise granulocyte colony stimulating
factor (G-CSF)-mobilized peripheral blood stem cells
(PBSCS). Patients were monitored prospectively in
terms of clinical complications, including graft rejec-
tion, acute GVHD (aGVHD) and cGVHD, infection,
and relapse. This includes weekly cytomegalovirus
(CMV) pp65 antigenemia assays to monitor for
CMV reactivation during the first 3 months postgraft.
No prophylaxis or preemptive treatment for antigene-
mia in the absence of other clinical or biologic CMV-
related symptom was given.
Enumeration of CD41 and CD81 T Cell Subsets
One milliliter of the final graft product was
obtained immediately before infusion for evaluation
of graft composition. Peripheral blood samples were
collected from recipients 30 6 2, 60 6 3, 90 6 5,
1806 10, and 3656 15 days after allo-SCT. All living
patients had at least 3 samples analyzed. Whole-blood
and graft samples were stained without further separa-
tion shortly after collection, acquired by multiparame-
ter flow cytometry and categorized by their profiles of
CD45RA, CC-chemokine receptor-7 (CCR7), and
CD28 expression, as described previously [12,13]. All
reagents and instrumentation were from Beckman
Coulter (Fullerton, CA), with the exception of the
monoclonal antibody (mAb) to CCR7, from R&D
systems (Minneapolis, MN). Absolute counts and per-
centages of naı¨ve (CD45RA1 CCR71 CD281) and
differentiated T cells with a central memory (TCM,
CD45RAneg CCR71), effector memory (TEM,
CD45RAneg CCR7neg), and CD45RA1 effector mem-
ory (TEMRA, CD45RA
1 CCR7neg) phenotype [9]
were determined within the CD41 and the CD81
T cell populations. The proportion of cells coexpress-
ing CD28was determined within each of these subsets.
The degree of donor chimerism among CD31 T cells
was assessed by real-time polymerase chain reaction
(PCR) with a sensitivity\1% [14].
Statistical Analysis
Patient characteristics are presented as median
(range) unless otherwise stated. Normalization of the
absolute counts of a given lymphocyte population in
the peripheral blood of a patient was defined as reach-
ing the fifth percentile of age-matched reference values
of this laboratory [15]. The results were first summa-
rized with descriptive statistics, including medians
and interquartile ranges (25th-75th percentiles; inter-
quartile range [IQR]). An initial analysis of the data
was performed univariably using rank-order nonpara-
metric tests and log-likelihood ratio G-test or Fisher’s
exact test, as appropriate. Statistical correlations were
performed using Spearman’s rank test. For the patient
outcome study, probabilities were estimated by the
Kaplan-Meier product-limit method, and the log-rank
Table 1. Characteristics of donor/recipient pairs.
All Patients Complication Free* Only Relapse Only Chronic GVHD† P‡
No. of patients (male/ female) 80 (43 / 37) 18 (7 / 11) 15 (12 / 3) 13 (9 / 4) —
Age of recipients: median (range), years 32 (4-56) 24 (4-56) 33 (5-55) 25 (14- 55) NS
No. <16 years of age 15 6 4 2 NS
Underlying disease, no. of patients:§
Myelogenous proliferation (AML / CML / MDS) 53 (28/7/18) 14 (9 / 2/3) 9 (8 / — / 1) 6 (3 / 1 / 2) NS
Lymphoid proliferation (ALL / CLL / NHL) 27 (24/1/2) 4 (4 / — / —) 6 (6 / — / —) 7 (6 / 1 / —)
Age of donors: median (range), years 35 (2-63) 31 (2–58) 37 (9-55) 30 (9- 57) NS
Donor-Recipient sex mismatch, no.¶ 23 3 3 7 NS
Donor-Recipient CMV-serostatus (either or both positive), no. 49 12 7 9 NS
Donor/recipient pairs, no.:
HLA-identical sibling 54 14 9 11
HLA-identical (10/10), unrelated 20 4 4 2 NS
HLA-Cw mismatched (9/10), unrelated 6 — 2 —
Source of graft, no.:
Bone marrow 67 17 12 10
G-CSF-mobilized PBSC 13 1 3 3 NS
Infused CD34+ stem cells 107/ kg recipient’s weight: median (range) 2.98 (1.05-13.9) 3.38 (1.23-8.5) 3.44 (1.22-7.4) 2.69 (1.23- 8.5) NS
Infused T cells 106 / kg recipient’s weight: median (interquartile range):
all CD3+ T cells 24.3 (18.0-35.1) 22.5 (24.3-36.1) 27.9 (20.0-42.1) 27.1 (20.7-35.8) NS
CD4+ T cells 13.0 (8.8-18.4) 10.6 (6.0-14.8) 17.7 (9.8-22.7) 14.8 (11.2-19.5) NS
CD8+ T cells 11.0 (8.4-17.2) 10.0 (7.6-15.2) 13.0 (10.2-19.8) 11.0 (9.2-17.5) NS
Myeloablative conditioning regimens:t
Busulfan- Cyclophosphamide 32 12 4 4 .03
Cyclophosphamide—12-Gray TBI 48 6 11 9 **
Cyclosporine—short-term Methotrexate prophylaxis for acute GVHD, no. of patients: 80 18 15 13 —
Day 60 chimerism: median (interquartile range), percentage of donor T cells 98.5 (93-100) 96 (88- 99) 94 (98-100) 97.5 (96-100) NS
CMV reactivation, no. of patients: median (range) days postgraft: 15 — — —
45 (5-141)
Acute GVHD, no. of patients: median (range) days postgraft: 23 — — —
31 (13- 61)
Chronic GVHD, no. of patients: median (range) days postgraft: 30 — — 13
184 (57- 971) 202 (105-971)
Relapse, no. of patients: median (range), days postgraft: 26 — 15 —
217 (85- 561) 215 (95- 561)
Whole follow-up period: days postallograft 502 (64-1474) 897 (395-1564) 487 (122-841) 1012 (542-1389)
AML indicates acute myelogenous leukemia; CML, chronic myelogenous leukemia; GVHD, graft-versus-host dieases; C-GSF, granulocyte-colony stimulating factor; NHL, non-Hodgkin lymphoma; CMV, cytomega-
lovirus; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukeima; PBSC, peripheral blood stem cells; TBI, total body irradiation.
*Complication-free patients: those who did not develop any transplantation-related complication (severe infection, viral infection, acute or chronic GVHD, graft rejection) and who did not relapse over the whole
period of follow-up.
†Chronic GVHD without prior acute GVHD, scored according to standard criteria (10 limited, 3 extensive).
‡Comparisons between the 3 subgroups of patients, using the Kruskal-Wallis test or log-likelihood ratio G-test as appropriate.
§AML, CML in chronic phase and MDS without blast crisis; ALL, NHL (low grade). All patients with acute leukemia were in complete remission at the time of transplantation. Log-likelihood ratio G-test compared
AML/CML/MDS versus ALL/NHL.
¶Defined as a male patient undergoing transplantation with cells of a female donor.
tBusulfan plus cyclophosphamide (200 mg/kg) or cyclophosphamide (60 mg/kg) plus fractioned TBI (12 Gray).
**Post hoc test revealed a significant difference in the type of myeloablative conditioning regimen between the complication-free patients and those who only relapsed, whereas myeloablative preparative regimen did
not differ between patients who relapsed and those who had only cGVHD.
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Biol Blood Marrow Transplant 15:496-504, 2009 499CD81CD28neg T cells and Relapse after allo-SCTtest was used to evaluate differences between stratified
patient subgroups. Potential prognostic factors for
relapse were brought into a multivariate analysis using
Cox proportional-hazards model. Candidate risk fac-
tors included in the model were the logarithmic trans-
formation of lymphocyte subset counts, age of the
recipient, myeloablative conditioning regimen, source
of stem cells, donor-patient histocompatibility, disease
type, CMV serostatus, and all other clinical and bio-
logic factors as listed in Table 1. Results were con-
firmed using a competitive risk regression model [16].
All results were considered statistically significant at
the 5% level (2-sided).Figure 1. Median absolute counts of peripheral blood CD81 T cells (a)
and their CD28-negative subset (b) by days 30, 60, 90, 180, and 365 after
myeloablative HLA-matched allo-SCT, comparing patients free of any
clinical complication throughout 395 to 1564 days of follow-up (dia-
monds and thick solid line) with patients who experienced only cGVHD
(triangles and thin solid line) and patients with relapse (squares and
dashed line) exclusive of other complication. Error bars indicate the
25th to 75th percentiles. The number of patients studied who were
complication-free, who had only cGVHD or only malignant relapse
were 17, 13, and 14, respectively, on days 30; 18, 13, and 15 on day 60
and on day 90; 16, 13, and 10 on day 180; and 8, 10, and 8 on day 365.
Positions are depicted next to each other around the time point to pre-
vent overlaying 1 subgroup value with another. The horizontal dotted
line in (a) denotes the fifth percentile of reference values for the median
age of the recipients. *P # .05; **P # .01; ***P # .001 by Kruskal Wallis
test with Dunn’s posttest evaluation to compare complication-free pa-
tients with those who relapsed; differences between complication-freeRESULTS
Overall, 18 of the 80 myeloablative allo-SCT
recipients were free of any clinical complication by
the time of last follow-up (395–1564 days postgraft).
These patients less commonly received total body
irradiation (TBI) containing preparative regimen,
and all received grafts from 10 of 10HLA-matched do-
nors. Two other subgroups were distinguished, 1 with
only cGVHD and 1 with only relapse. These 2 sub-
groups were comparable as regards the proportion of
patients younger or older than 16 years of age, of pa-
tients receiving preparative TBI, of marrow versus
PBSC allografts, and of sibling versus unrelated do-
nors. There were, however, 2 patients who relapsed af-
ter receiving a graft with 1 HLA-Cw mismatch,
whereas all patients in the subgroup with only
cGVHD received a 10 of 10 HLA-matched allograft
(Table 1).patients and patients with only cGVHD were not significant whatever
the time point.Recovery of T Cell Subsets in Long-Term
Complication-Free Patients
Inasmuch as immune recovery can be affected by
the occurrence of postgraft complications and their
treatment, the long-term complication-free patients
allowed assessing T cell reconstitution in the absence
of interfering factors. Absolute counts of CD41T cells
remained below the fifth or the 10th percentile of age-
matched reference values throughout the first year
postgraft, with subsequent reversal of the normal
CD4:CD8 ratio (not depicted). Absolute counts of
CD81T cells increased rapidly, reaching the fifth per-
centile of age-matched reference values within 3
months in 8 of the 18 complication-free patients and
otherwise by 6 months (Figure 1a). Virtually all circu-
lating T cells were of donor origin (Table 1). There
were no significant differences in the rate of recovery
comparing complication-free patients younger or
older than 16 years of age, marrow, and PBSC grafts,
sibling and unrelated donor status, and whether mye-
loablative conditioning regimen included TBI or not.At all time points the vast majority of circulating T
cells were lacking CC-chemokine receptor-7 (CCR7)
expression, indicative of an effector memory-like phe-
notype.Within theCD41 population, theCD45RAneg
CCR7neg TEM phenotype was disproportionately
abundant, resulting in an inversion (median of 0.42
by day 60; IQR 0.30-0.70) of the normal TCM:TEM ra-
tio evidenced in the corresponding graft sample (1.42;
IQR: 0.67-2.49) and in age-matched healthy controls.
Within CD81 T cells, TEM represented a median of
25.9% of all CD81 T cells (IQR 16.6%-39.6%) and
CD81 TEMRA 49.6% (IQR 45.4%-66.1%) by day 60
postgraft.
Circulating CD81 lacking CD28 expression accu-
mulated steadily over the first year (Figure 1b).
Whether in adult or in younger recipients, the
percentages of CD28neg CD81 T cells oversized the
percentages determined in paired graft samples, what-
ever the memory-type subset and whatever the elapsed
500 Biol Blood Marrow Transplant 15:496-504, 2009I. Yakoub-Agha et al.time since transplantation (P# .003 by Friedman test).
There was no significant correlation between the total
number of CD81 T cells infused with the graft and
absolute counts of peripheral blood CD28neg CD81
T cells in the recipient (r 5 .09; P 5 .75 by day 60).
Overall, CD28neg cells predominated within the
CD81TEM andTEMRA subsets and altogether peaked
at a median of 69.4% (IQR 54.5%-78.5%) of all CD81
T cells by day 60. The proportion of CD28neg CD81
T cells slightly diminished thereafter to a median of
55.2% (IQR 41.3-56.8) by day 365, still remaining
within the upper quartile of reference values in adult
recipients, whereas pediatric patients kept throughout
a higher percentage than normal for their age. Abso-
lute numbers of CD28neg CD81 T cells in patients
who were younger than 16 years of age at time of trans-
plantation and those 16 years and older were com-
pared, but no statistically significant difference was
evidenced (P5 .09 by a Mann-Whitney test). All these
18 recipients were devoid of clinical and biologic signs
of CMV reactivation, and combinations of donor and
recipient CMV serostatus were not significantly asso-
ciated to circulating CD28neg CD81 T cell counts.Recovery of T Cell Subsets in Patients with
cGVHD
Peripheral blood CD41 T cell counts increased as
slowly and CD81 T cell counts as rapidly in patients
who developed de novo cGVHD as in the complica-
tion-free subgroup (Figure 1a). Frequencies of CD41
and CD81 T cell subsets, as categorized by their
profiles of CD45RA and CCR7 expression, were also
substantially similar (data not shown). Absolute num-
bers and percentages of CD81 T cells lacking CD28
expression tended to be higher by day 60, but there
was substantial overlap with values from the complica-
tion-free subgroup, and formal statistical significance
was not achieved (Figure 1b). The difference remained
nonsignificant when the comparison included only
patients who underwent bone marrow transplantation.
Individual CD41 and CD81 T cell subsets in periph-
eral blood sampled after cGVHD was diagnosed were
compared with values from the complication-free
subgroup sampled at similar times. No statistically
significant difference was evidenced, even if the
patients with ongoing cGVHD tended to have greater
numbers of CD28neg CD81 T cells by day 365
(P 5 .09).
There were 7 patients who had aGVHD preceding
cGVHD without other clinical complications. Their
median count of CD28neg CD81 T cells was 180 per
mm3 (range: 140-246) at day 60 (P 5 .44 compared
with patients experiencing de novo cGVHD). Includ-
ing these patients together with those with de novo
cGVHD did not evidence a significant difference
with the complication-free subgroup.Recovery of the Main T Cell Subsets in Patients
Who Relapsed
Full donor T cell chimerism was achieved among
all patients who relapsed exclusive of any other clinical
event (Table 1). Relative and absolute counts of CD41
T cells and their subsets were low and evolved similar
to those of complication-free patients (data not
shown). Absolute counts of CD81 T cells increased
more slowly (Figure 1a), at around half of the values
from complication-free patients, with subsequent
higher CD4:CD8 ratios. There was a trend toward
a smaller percentage of cells with a CD81 TEMRA
phenotype that achieved formal statistical significance
(P 5 .01) only on day 90 postgraft. Absolute numbers
and percentages of all CD81 T cells lacking CD28
expression were significantly diminished from day 30
onward (Figure 1b). The median percentage of
CD28neg CD81 T cells represented around 1/4th
that of complication-free patients at all time points.
The 3 patients who relapsed after receiving PBSC
grafts had as low CD28neg CD81 T cell numbers as
those who relapsed after marrow grafts (range at day
60: 46-165 and 6-227/mm3, respectively; P 5 .78).
Five additional patients relapsed 71 to 316 days
after being diagnosed first with de novo cGVHD.
Their CD81 T cell counts and absolute numbers
and percentages of CD28neg CD81 T cells (median
of 94/mm3 at day 60) ranged intermediate between
corresponding values from the patients who relapsed
without previous cGVHD (median of 47.5/mm3) and
the patients who were devoid of any clinical complica-
tion (median of 179/mm3).Univariate and Multivariate Analysis of Factors
Affecting Relapse
All the patient and donor factors listed in Table 1
as potential predictors of relapse fell short of signifi-
cance at the .05 level in univariate analysis comparing
the subgroups of patients without complication, with
only cGVHD and with only relapse. Although the pro-
portion of patients receiving preparative TBI was
lower in the complication-free subgroup, it was com-
parable between patients who experienced cGVHD
and those who relapsed. Likewise, the proportion of
patients receiving PBSC instead of bone marrow grafts
was similar between patients with cGVHD and those
who relapsed (Table 1).
Risk of developing relapse was further examined
univariably at day 60 postgraft by categorizing all the
80 patients by the median of CD28neg CD81 T cell
counts from the complication-free subgroup (179
cells/mm3). Using day 60 values was elected because
a complete set of phenotypic analyses was available
for all the recipients at this time point, whereas some
values were missing on day 30, because of insufficient
lymphocyte counts for detailed subset analysis. All
Biol Blood Marrow Transplant 15:496-504, 2009 501CD81CD28neg T cells and Relapse after allo-SCTbut 5 of the 26 patients who subsequently relapsed had
absolute numbers of CD28neg CD81 T cells \179
cells/mm3, a significant difference by log-rank test
(Figure 2).
Cox regression analysis for relapse as the endpoint
was performed to compare the effect of recovering low
CD28neg CD81 T cell counts with the recipient age
and disease type, the presence or absence of TBI in-
cluded in the myeloablative conditioning regimen,
the donor type (sibling versus unrelated), the source
of stem cells (marrow versus PBSC), and quantities
of CD81T cells infused into patients. Prior to all anal-
yses, proportional hazard assumptions were tested and
met in the subgroups with and without relapse. Con-
sidering the entire patient cohort, likelihood of relapse
correlated inversely with absolute CD28neg CD81 T
cell counts by day 60 (n 5 80, adjusted hazard ratio
of 0.33; 95% confidence interval [CI]: 0.14-0.76;
P 5 .01). CD28neg CD81 T cell counts being predic-
tive of relapse was confirmed by competitive risks re-
gression analysis after adjustment for the other
factors presented inTable 1 (P5 .01). The inverse cor-
relation was also verified by day 90 (0.29; 95%CI 0.13-
0.65; P 5 .003).
None of the donor and patients characteristics was
significantly associated with relapse in multivariate
modeling. Marrow graft transferred fewer numbers
of mature T cells to the recipient than did G-CSF
mobilized PBSC. However, when patients who
received PBSC grafts were excluded and only marrow
recipients were tested in a multivariate model, the
inverse correlation between likelihood of relapse and
low absolute CD28neg CD81 T cell counts by day 60
remained strong (hazard ratio: 0.41; P 5 .02). Like-
wise, not including in the model the patients who
relapsed after receiving a graft mismatched at 1
HLA-Cw locus still evidenced only CD28neg CD81
T cell counts as associated with relapse (hazard ratioFigure 2. Kaplan-Meier estimate of malignant relapse after myeloabla-
tive HLA-matched allo-SCT. The 80 patients were categorized as having
absolute CD28neg CD81 T cell numbers by day 60 postgraft falling lower
(solid line) versus equal to or higher than (dashed line) the median (179
CD28neg CD281 T cells/mm3 of peripheral blood) determined in the
subgroup of 18 patients free of any clinical complication by the time of
last follow-up. The P value is for the log-rank test.0.33; P 5 .03). Finally, when pediatric patients were
excluded to analyze patients aged 16 years or older at
the time of transplantation, the inverse correlation
between likelihood of relapse and CD28neg CD81 T
cell counts was still significant (hazard ratio 0.29;
P 5 .03).DISCUSSION
Successful T cell recovery substantially reduces
morbidity andmortality following allo-SCT for hema-
tologic malignancies, but disease relapse and cGVHD
remain major causes of late morbidity and mortality.
This prospective analysis found that poor CD81 T
cell recovery with diminished absolute CD28neg
CD81T cell counts in the first 2 months after myeloa-
blative allo-SCTwas significantly associated with later
development of malignant relapse, whereas patients
who developed progressive or de novo cGVHD with-
out relapsing recovered T cell counts similar to pa-
tients free of any clinical complication.
The subgroup of patients who did not develop any
transplantation-related complication and who did not
relapse over a period of follow-up longer than 1 year
allowed analyzing the kinetics of T cell reconstitution
in the absence of possible interferences by infections
and GVHD that can affect the number and memory
phenotypes of T cells [10,17]. As expected, absolute
counts of CD41 T cells remained low throughout the
first year posttransplantation, whereas absolute counts
of CD81 T cells increased rapidly over 3 to 6 months,
however, with predominance of cells lacking CCR7
and CD28 expression and persisting low levels of cells
with a naı¨ve (CD45RA1 CCR71 CD281) phenotype.
There were presumably too few pediatric recipients
in this series to detect any effect of age on recovery
over the first year posttransplantation, but it is known
that renewal of thymopoiesis cannot be evidenced be-
fore 6months in young children and is slower in adoles-
cents [3,5]. Accordingly, for the first several months
after myeloablative transplantation, the number of cir-
culating T cells depends primarily on homeostatic pe-
ripheral expansion rather than on the thymic function.
There were also too few PBSC recipients to detect any
faster recovery effect of this source of graft. As regards
CD28negCD81Tcells, however, their absolute counts
were reported to be similar in the first year in marrow
and in PBSC recipients [18]. Bonemarrow grafts trans-
fer around 10 times less mature T cells to the patient,
but 3 to 4 more cell divisions would suffice to yield
the same count of CD28neg CD81T cells as in patients
given PBSC grafts. CMV-specific CD81 T cells
predominantly reside in the CCR7neg and CD28neg
subsets [10], and we cannot formally exclude that
CMV-reactive T cells disproportionately expanded
whenever the donor and/or the recipient was
502 Biol Blood Marrow Transplant 15:496-504, 2009I. Yakoub-Agha et al.CMV-seropositive.However, this subgroupof patients
was devoid of clinical and biologic signs of CMV reac-
tivation, and there was no significant association be-
tween levels of CD28neg CD81 T cells and
combinations of donor and recipient CMV serostatus.
Homeostatic cytokines can also induce a stable loss of
CD28 expression on expanding CD81 T cells
[19,20], which in the absence of CMV disease suggests
that homeostatic peripheral expansion directly con-
tributed to the generation and accumulation of
CD28neg CD81 T cells throughout the first year after
allo-SCT. Accordingly, sustained accumulation of
CD28neg CD81 T cells has been reported after high-
dose chemotherapy or depleting mAb [4,21,22].
Kinetics of T cell reconstitution in patients who
developed cGVHD was fairly similar to that in
complication-free recipients. It is generally considered
that the continuing risks of developing cGVHD may
persist until 12 or 15 months postgraft. Our follow-
up period was longer, so that incidence of symptomatic
cGVHD was not underestimated. Our observation
confirms earlier reports showing that CD81 T cell
counts tended to be higher [23] or not significantly
associated [24] with cGVHD, and that patients with
poor early lymphocyte recovery were not at higher
risk of aGVHD or cGVHD [25]. A few cross-sectional
studies have variously reported on decreased CD41
TCM [26,27], elevated CD4
1 TEM [26], increased
[28] or decreased [29] CD81 TCM, and increased
CD81 TEMRA [29], in patients who had cGVHD at
time of sampling. There also exists uncertainty on
whether the proportion of CD81 T cells lacking
CD28 (or the overlapping CD571 subset) is increased
[30] or not [24] during ongoing cGVHD.One possible
explanation is that all these reports analyzed mononu-
clear cells (instead of whole blood as in this study),
given that Ficoll purification can induce a bias in subset
distribution, particularly among CD81 T cells [31].
Another difference is that some reports included pa-
tients after nonmyeloablative conditioning, who could
be generally less lymphopenic, and therefore undergo-
ing lesser homeostatic peripheral expansion.
cGVHD may involve both alloreactivity and au-
toreactivity against the host [3]. In fully HLA-matched
donor/recipient pairs, donor T cells that have gone
through homeostatic peripheral expansion while being
exposed to ubiquitous minor histocompatibility anti-
gens or self-peptides on host cells could be driven to
differentiate into alloreactive effectors or to display
pathogenic autoreactivity [32], respectively. Patients
who will go on to develop cGVHD might therefore
be expected to accumulate memory-like T cells at least
as quickly as patients who undergo immune reconsti-
tution without massively expanding pathogenic
clones, notwithstanding expected differences in the
respective clonal composition of their peripheral
T cells [33,34].Contrary to cGVHD, malignant relapse was con-
sistently preceded by diminished absolute CD81 T
cell counts, at around half of the values from patients
who did not relapse. This is in agreement with other
reports showing that marrow recipients with a high re-
population of CD81 T cells have a lower incidence of
leukemia relapse [25,35]. Absolute CD28neg CD81 T
cell counts were diminished at 1/4th of that of patients
who did not relapse. This difference was significant
from 30 days onward, long before the patients went
on to relapse (at a median of 215 days in the patients
who relapsed without prior cGVHD and after 152
days or more in the patients with cGVHD preceding
relapse). Multivariate proportional hazard analyses
revealed low absolute CD28neg CD81 T cell counts
by day 60 postgraft as the only significant risk factor
of malignant relapse, and their predictive value was
confirmed by using competitive risk multivariate mod-
eling. All patients included in this study were trans-
planted in complete hematologic remission at
transplantation, the distribution of underlying diseases
was comparable whether or not patients went on to
relapse, and no patient was at high risk of relapse.
The proportion of PBSC recipients in subgroups
that did or did not relapse was also comparable. Fur-
thermore, multivariate proportional hazard analysis
including only bone marrow recipients confirmed the
inverse correlation between likelihood of relapse and
absolute CD28neg CD81 T cell counts by day 60.
The GVL effect to prevent relapse can be medi-
ated variously by donor-derived T cells and natural
killer cells. Missing killer immunoglobulin-like recep-
tor recognition is not expected to predominate after 10
of 10 HLA-matched grafts, and excluding from multi-
variate analysis the few patients receiving a graft with 1
HLA-Cw mismatch did not ablate the significance of
the association between CD28neg CD81 T cell counts
and risk of relapse. Homeostatic proliferation follow-
ing lymphopenia may facilitate expansion of antitumor
immunity. Then, insufficient expansion might result
from insufficient interaction of donor T cells with
antigens present in the host, including hematopoietic
tissue-restricted minor histocompatibility antigens
and leukemia-specific antigens that would expand
tumor-specific T cell clones [1,6,7]. CD28neg CD81
T cells are endowed with high cytotoxic capacities
and diversified cytokine production [8-11]. Lower
absolute CD28neg CD81T cell countsmight therefore
reflect lesser generation of T cells with eradicating po-
tential against the hematologic malignancy, whether
directly or through a reduced bystander (cytokine-
dependent) effect.
This prospective study is the first to associate
a diminished absolute number of circulating CD28neg
CD81 T cells with a greater risk of malignant relapse
after a myeloablative conditioning. Enumeration of
circulating CD81 T cells lacking CD28 expression
Biol Blood Marrow Transplant 15:496-504, 2009 503CD81CD28neg T cells and Relapse after allo-SCTby day 60 postgraft could assist in predicting risk of
relapse. This can help build an algorithm aimed at
accelerating the immune recovery by reducing the in-
tensity of posttransplant immunosuppressive regimen
[36] and considering the introduction of posttrans-
plant immunotherapy (preemptive donor lymphocyte
infusions [DLI]) to overcome the risk of disease relapse
after the acute risks of allo-SCT have passed.ACKNOWLEDGMENTS
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